Samples from metastatic melanoma patients treated sequentially with immunotherapies targeting CTLA4 and PD-1 pointed to response-related tumor features.
The company signed separate agreements with AstraZeneca, Merck, Merck KGaA, and Pfizer to create the panel, which is expected to help speed drug development.
A subset of mutation-associated neoantigens appeared to be lost from lung or head and neck tumors that became resistant to anti-PD1 or anti-PD1 and anti-CLTA4 therapy.
The firm's vaccine, which previously led to tumor regression in a patient with metastatic breast cancer, is scheduled to enter clinical trials in 2017.
The platform will be designed to gather all necessary data from a single RNA extraction, eliminating the need for flow cytometry, genomic sequencing, and expression profiling.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
